DCM
NKTR icon

Driehaus Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Driehaus Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-391
Closed -$350K – 555
2017
Q4 		$350K Buy
+391
New +$231K 0.01% 449
2016
Q4 		– Sell
-6,138
Closed -$1.58M – 615
2016
Q3 		$1.58M Buy
+6,138
New +$1.58M 0.05% 300
2013
Q4 		– Sell
-7,878
Closed -$1.23M – 502
2013
Q3 		$1.23M Sell
7,878
-2,250
-22% -$416K 0.05% 336
2013
Q2 		$1.75M Buy
+10,128
New +$1.55M 0.08% 284

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Driehaus Capital Management's NKTR Position: Q1 2018 in Review

Driehaus Capital Management sold out of Nektar Therapeutics (NKTR) in Q1 2018, closing a stake of 391 shares — an estimated $350K sold.

Driehaus Capital Management first reported a position in NKTR in Q2 2013 and held it in 4 quarters. The position peaked at $1.75M in Q2 2013. 358 funds tracked by Wall St. Rank hold NKTR as of Q1 2018.

  • Driehaus Capital Management reported no remaining Nektar Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Driehaus Capital Management sold 391 Nektar Therapeutics shares in Q1 2018, an estimated $350K.
  • Driehaus Capital Management first reported a position in Nektar Therapeutics in Q2 2013 and held it in 4 quarters.
  • Driehaus Capital Management's Nektar Therapeutics position peaked at $1.75M in Q2 2013.
  • 358 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2018.

Based on Driehaus Capital Management's 13F filing for Q1 2018, filed 15 May 2018.